Results 161 to 170 of about 42,196 (291)

Dissecting the dissection laboratory: Elements for designing a human anatomy laboratory

Anatomical Sciences Education, EarlyView.
Abstract The human anatomy dissection laboratory is a critical component of anatomical and medical education. Development, maintenance, and stocking of these laboratory spaces have unique demands, with all of the challenges in running a laboratory with Biosafety Laboratory Level 2 (BSL‐2) classification, housing a large volume of tissues saturated with
Rhiannon E. Robinson, Abbey Breckling, Danielle N. Edwards, Nicole Geske, Burhan Gharaibeh, Bobbie J. Leeper, Molly Ostwald, Mary Schilling, Bridgett Severt, Kelsey Stevens, J. P. Swigart, Jonathan J. Wisco, Melissa Zolnierz, Jeremy J. Grachan   +13 more
wiley   +1 more source

Duloxetine repositioning: Investigation of antifungal and antibiofilm activity against fluconazole-sensitive and resistant Candida Spp. strains. [PDF]

Braz J Microbiol
Barbosa SA, Pinheiro DRS, de Oliveira LC, de Almeida Moreira LE, Cabral VPF, Rodrigues DS, de Souza BO, Nobre Júnior HV, Sa LGDAV, Cavalcanti BC, Magalhães IL, de Oliveira Ferreira JR, de Moraes MO, de Andrade Neto JB, da Silva CR.   +14 more
europepmc   +1 more source

Efficacy and safety of empagliflozin for treating neutropenia and neutrophil dysfunction in paediatric patients with glycogen storage disease type Ib: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aims Glycogen storage disease type Ib (GSD‐Ib) is a rare genetic disorder causing neutropenia and neutrophil dysfunction in children. G‐CSF has been the primary treatment, but emerging data support the potential of empagliflozin, an SGLT2 inhibitor, as a promising investigational option.
Elizabeth Iwasyk, Ryan Jin, Fabio Tuzzolino, Giusy Ranucci, Donatella Madonia, Alessio Provenzani   +5 more
wiley   +1 more source

Economic Burden and Cost Differences Between Branded and Generic Topical Antifungals in India. [PDF]

Cureus
Dt P, Dongerkery K, Deolekar P, Dahibhate A, V S, Mohammed Shahid S, Ananthanarayan A, Vadhavekar NH.   +7 more
europepmc   +1 more source

Characteristics and temporal trends of EU teratological safety signals and information dissemination to healthcare professionals in the Netherlands—A contribution of the ConcePTION project

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Although regulatory responses to safety signals have been studied, pregnancy‐specific data and their dissemination to medical professionals remain unclear. This study examined the characteristics and temporal trends of teratological safety signals prompting the European Medicines Agency to implement risk minimization measures.
Yrea R. J. van Rijt‐Weetink, Rosanne E. Huisman, Jan‐Peter van Wieringen, H. J. M. J. (Ineke) Crijns, Florence P. A. M. van Hunsel, Anneke L. M. Passier, Sander Borgsteede, A. C. G. (Toine) Egberts, Laura M. Yates, Eugène P. van Puijenbroek   +9 more
wiley   +1 more source

Establishment of epidemiological cutoff values against <i>Fonsecaea monophora</i>, an agent of chromoblastomycosis and cerebral phaeohyphomycosis. [PDF]

J Clin Microbiol
Smith DJ, van Beurden T, Li Y, Almeida-Paes R, Jacomel B, Vicente VA, Lustosa BPR, Walter TH, Neto ENM, Hallur V, Paul D, Paul N, Li R, Lu S, Kidd SE, Bonifaz A, Samaddar A, Treviño-Rangel RdJ, González GM, Chowdhary A, Brunellie JGP, García-Effron G, Rudramurthy SM, Kaur H, Chakrabarti A, de Azevedo CdMPeS, Marques SG, Santos DWCL, Cognialli RCR, Queiroz-Telles F, Spruijtenburg B, Meijer EFJ, de Groot T, Seyedmousavi A, Dufresne PJ, Lockhart SR, Wiederhold NP, Song Y, Hagen F.   +38 more
europepmc   +1 more source

Evaluation of a pantoprazole and 4‐desmethylpantoprazole‐sulfate metabolic ratio as a novel CYP2C19 phenotyping method

British Journal of Clinical Pharmacology, EarlyView.
Aims CYP2C19 is one of the most important pharmacogenes, and its activity is highly variable due to factors such as genetics or drug–drug interactions. Due to the lack of an appropriate endogenous CYP2C19 biomarker, surrogate methods to assess its activity are warranted.
Julian Peter Müller, Vladimir N. Belov, Sabrina Yamoune, Bob Miller, Mohammed Hasoumi, Jolanta Tupiec, Thea Laurentius, L. Cornelius Bollheimer, Julia C. Stingl, Katja S. Just   +9 more
wiley   +1 more source

Manogepix demonstrates potent <i>in vitro</i> activity against <i>Aspergillus, Coccidioides</i>, <i>Scopulariopsis/Microascus, Rasamsonia</i>, and <i>Purpureocillium</i> species, including strains with <i>in vitro</i> resistance to other antifungals. [PDF]

Antimicrob Agents Chemother
Wiederhold NP, Patterson HP, Sanders C, Canete-Gibas C.   +3 more
europepmc   +1 more source

Relationship between continuous infusion meropenem PK/PD target attainment and C‐reactive protein dynamics in onco‐haematologic patients with febrile neutropenia

British Journal of Clinical Pharmacology, EarlyView.
Aim Meropenem is a second‐line antimicrobial agent in the treatment of febrile neutropenia in onco‐haematological patients. A population pharmacokinetic/pharmacodynamic (PK/PD) analysis for assessing the relationship between meropenem exposure and C‐reactive protein (C‐RP) over time was conducted.
Chun Liu, Pier Giorgio Cojutti, J. G. Coen van Hasselt, Michele Bartoletti, Maddalena Giannella, Pierluigi Zinzani, Pierluigi Viale, Federico Pea   +7 more
wiley   +1 more source

Beyond the review: additional non-oncologic drugs with clinically significant cardiovascular effects. [PDF]

Eur Heart J Cardiovasc Pharmacother
Van der Linden L, Vanassche T.
europepmc   +1 more source